CTRI/2010/091/000435招募中未知
Clinical Study on the use of ex vivo expanded Allogenic Mesenchymal Stem Cells for Cerebral Palsy
ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A' Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion of patients for therapy will be under the investigators discretion. However the following criteria will be considered.
- •- Must be more than 2 years of age and less than 15 years of age at the time of screening for inclusion in the study.
- •- Clinical evidence of a non-progressive motor disability due to brain dysfunction. The subjects will not have the ability to sit independently by one year of age or the ability to walk by 18 months of age.
- •- Willing to comply with all study procedures.
- •- The patients must be seizure-free or seizures adequately controlled. If there is a suspicion of seizures and EEG should be done prior to inclusion.
排除标准
- •Exclusion of patients from therapy will be under the investigator?s discretion. However the following criteria will be considered
- •1. Have complicating medical issues that would interfere with blood drawing, such as venous access so limited that success is unlikely
- •2. Presence of obstructive hydrocephalus.
- •3. Presence of progressive neurological disease.
- •4. Presence of known chromosomal anomaly
- •5. Presence of major congenital anomaly
- •6. Evidence of illness on planned infusion date (such as but not limited to fever >38.5, vomiting, diarrhea, wheezing, or crackles)
- •7. Use of immunosuppressive drugs
- •8. Evidence of known genetic disorder
研究者
相似试验
招募中
不适用
Clinical study on the use of ex vivo expanded allogeneic mesenchymal stem cells for Parkinson's diseaseCTRI/2010/091/000432ADVANCED NEURO-SCIENCE ALLIES PVT. LTD#560, Bhargavi, 9th "A" Main, Indiranagar, Bangalore-560 038Karnataka (INDIA)15
已完成
1 期
Immune cell therapy for patients with COVID-19 related pneumonia using allogenic ex vivo NK cellsIRCT20200621047859N2Motamed Cancer Institute15
尚未招募
1 期
atural Killer imune cells expansion for Acute Myeloid Leukemia treatment.Acute myeloid leukaemia Myelodysplastic syndrome, unspecifiedD46.9C92.0RBR-8qq5h9Hospital Israelita Albert Einstein
已完成
不适用
Study of effectiveness of a day cream product in combination with a night cream in reducing dark spots in asian adult females over a period of 3 monthsCTRI/2012/02/002420Oriflame Research and Development Ltd36
招募中
1 期
A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphomarelapsed/refractory CD20 positive B-cell lymphomaJPRN-UMIN000014072Department of Hematology, Tokyo Women's Medical University10